Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

doi:10.1002/cncr.31314

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Cancer - 15 May 2018

Agarwal Neeraj, Pal Sumanta K, Hahn Andrew W, Nussenzveig Roberto H, Pond Gregory R, Gupta Sumati V, Wang Jue, Bilen Mehmet A, Naik Gurudatta, Ghatalia Pooja, Hoimes Christopher J, Gopalakrishnan Dharmesh, Barata Pedro C, Drakaki Alexandra, Faltas Bishoy M, Kiedrowski Lesli A, Lanman Richard B, Nagy Rebecca J, Vogelzang Nicholas J, Boucher Kenneth M, Vaishampayan Ulka N, Sonpavde Guru, Grivas Petros

Abstract excerpt

BACKGROUND: Biomarker-guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell-free circulating DNA (cfDNA) next-generation sequencing (NGS) readily available in the clinic. The objective of the current study was to determine whether the genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Circulating Tumor DNA

Share to DNA Mutational Analysis

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Urologic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29517810
DOI: 10.1002/cncr.31314
PMCID: PMC6857169

Genes

ERBB2
FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.PMID 29517810Read ↗

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read ↗

Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinomaSemantic proximity Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.Semantic proximity Read ↗

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaSemantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.Semantic proximity Read ↗

NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.Semantic proximity Read ↗

Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.